|
|
Article: Prostate Cancer - Hormone-Refractory Patients Still Waiting for Treatment Breakthroughs.
- Article from:
- Business Wire
- Article date:
- January 9, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK -- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
Stakeholder Insight: Prostate Cancer - Hormone-refractory patients still waiting for treatment breakthroughs
To order that report:
www.reportlinker.com/p073694/Stakeholder-Insight-Prostate -Cancer---Hormone-refractory-patients -still-waiting-for-treatment-breakthroughs.html
For more information, contact Nicolas by email nbo@reportlinker.com , by phone +33 4 37 65 17 03.
As a result of market dominance by agents such as leuprolide, and AstraZeneca's Zoladex (goserelin) and ...